HK Stock Market Move | HBM HOLDINGS-B(02142) rose over 8% in early trading. The company signed a BD transaction with Bausch Health worth over 1 billion USD.

In the early trading session, HBM Holdings-B(02142) rose by more than 8%, and as of the time of writing, it had risen by 6.79% to 13.36 Hong Kong dollars, with a trading volume of 25.2071 million Hong Kong dollars. On the news front, Hengbo Pharmaceutical announced that it has entered into a long-term global strategic cooperation and licensing agreement with Bristol-Myers Squibb to discover and develop a new generation of multispecific antibodies. Under the agreement, Hengbo Pharmaceutical will receive an initial payment of 90 million US dollars, and if Bristol-Myers Squibb advances all potential projects, the company is eligible to receive up to 1.035 billion US dollars in development and commercial milestone payments as well as tiered royalties. According to the terms of the agreement, both parties will collaborate to advance and accelerate the discovery of multispecific antibodies. It is worth noting that since 2025, Hengbo Pharmaceutical has secured three large orders from MNCs. At the beginning of the year, the company entered into a major cooperation agreement with AstraZeneca for up to 4.575 billion yuan, involving the development of multiple targets and projects, with the latter investing 105 million US dollars in equity and establishing a Beijing Innovation Center for deeper collaboration. In June, Hengbo Pharmaceutical reached a global strategic cooperation agreement with Otsuka Pharmaceutical for BCMAxCD3 bispecific T cell engager (HBM7020). It is reported that Hengbo Pharmaceutical has reached cooperation agreements with MNCs seven times, with a total external cooperation amount exceeding 10 billion US dollars.